Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715910 · ClinicalTrials.gov registry record · Phase 2
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 818
- Enrollment target
NCT00715910 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 818 participants.
The verdict
NCT00715910, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 818 participants
- Enrollment target
Study Summary
In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 and Menactra® in a previous study (whose objectives \& outcome measures are presented in a separate protocol posting with NCT number =00454909) will be evaluated. The safety and immune response to a booster dose of vaccine GSK134612 administered at 5 years post-primary vaccination and a primary vaccination of a newly enrolled group with GSK 134612 vaccine will also be evaluated.
Interventions
- PROCEDURE Blood sampling
- BIOLOGICAL Nimenrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 818 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715910
The ClinicalTrials.gov registry entry for NCT00715910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 818 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood sampling is the first listed.
NCT00715910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00715910 about?
NCT00715910 is a clinical study titled "The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults". In this study, the concentration of antibody to the vaccine one year, three and five years after vaccination in subjects who were vaccinated with GSK Biologicals' meningococcal vaccine GSK134612 and Menactra® in a previous study (whose objectives \& outcome measures are presented in a separate proto...
What is the current status of trial NCT00715910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 818 participants. The study started on 2008-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00715910?
The interventions under investigation include: Blood sampling (PROCEDURE), Nimenrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00715910?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.